Data shows AstraZeneca's Brilinta reduces risks of clinically relevant bleeding
New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that Brilinta monotherapy reduced the risk of clinically relevant bleeding compared to dual antiplatelet therapy, or DAPT, over 12 months in high-risk patients with non-ST elevation acute coronary syndromes. Results of the TWILIGHT sub-analysis were presented in a late breaker oral presentation on November 17 at the American Heart Association, or AHA, Scientific Sessions 2019 in Philadelphia. Danilo Verge, VP Global Medical Affairs, Cardiovascular, Renal and Metabolism said, "The TWILIGHT trial provided important information about the longer-term management of high-risk patients who had undergone PCI. In this pre-specified subgroup analysis of patients with NSTE-ACS enrolled in TWILIGHT, treatment with ticagrelor monotherapy, without aspirin, after three months of DAPT was associated with a lower risk of bleeding compared with standard 12 months of dual antiplatelet therapy with ticagrelor plus aspirin."